Alpha Cognition (NASDAQ:ACOG) Posts Earnings Results, Misses Expectations By $0.01 EPS

Alpha Cognition (NASDAQ:ACOG) posted its quarterly earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01), reports. The company had revenue of $7.78 million during the quarter, compared to analyst estimates of $7.04 million. Alpha Cognition had a negative net margin of 147.26% and a negative return on equity of 50.90%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL generated $7.8 million in Q3 net product revenue, up approximately 30% sequentially, with filled prescriptions up about 31%. Prescriber and facility adoption also grew, and the company exceeded its original full-year prescriber goal one quarter early.
• Commercial productivity improved as more than half of targeted prescribers wrote ZUNVEYL in Q3, repeat prescribing increased, and average prescriptions per writer rose to about seven. Management says growth is coming from both new customers and deeper use among existing prescribers.
• Formulary coverage was unchanged from prior quarters, and management does not expect a formulary win before year-end, though it hopes for traction early in 2027. The company says prior authorizations remain a friction point, even as its team reports a 95% approval rate when it supports the process.
• Management reiterated its goal of operating profitability in 2027, citing revenue growth outpacing spending, essentially flat sequential operating expenses, and $37.8 million in cash with no debt. It reaffirmed 2026 operating-expense guidance of $50 million–$54 million but did not provide revenue guidance.
• The company highlighted early real-world evidence showing higher therapeutic-dose attainment and fewer medication classes among ZUNVEYL residents, while noting that additional CONVERGE updates and publication are expected in 2027. A sublingual-formulation PK study was inconclusive, prompting another study planned for early 2027.

Alpha Cognition Stock Up 0.2%

Shares of NASDAQ ACOG opened at $8.63 on Friday. The firm has a market cap of $188.07 million, a price-to-earnings ratio of -6.30 and a beta of 2.32. Alpha Cognition has a 52-week low of $4.50 and a 52-week high of $10.14. The business’s 50 day moving average is $8.76 and its two-hundred day moving average is $7.27.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. B. Riley Financial initiated coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They set a “buy” rating and a $21.00 target price on the stock. Craig Hallum reiterated a “buy” rating and issued a $17.00 target price on shares of Alpha Cognition in a report on Friday, August 14th. Raymond James Financial set a $21.00 price target on shares of Alpha Cognition and gave the company an “outperform” rating in a research note on Thursday. Finally, HC Wainwright increased their price target on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Five equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Alpha Cognition currently has an average rating of “Buy” and an average target price of $18.20.

Insider Activity at Alpha Cognition

In other news, Director Robert Wills acquired 10,000 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was acquired at an average cost of $9.62 per share, with a total value of $96,200.00. Following the completion of the purchase, the director owned 32,241 shares of the company’s stock, valued at $310,158.42. This represents a 44.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 8.60% of the stock is currently owned by corporate insiders.

Alpha Cognition Company Profile

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.